SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001709941

BIOA

BioAge Labs, Inc.
$6.81 ▼ -3.95%
Prev close $7.09
Market cap$327.7M
ConsensusStrong Buy
12-mo target$35.63 (+423.1%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)33 New Institutional Positions7 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on BIOA right now — valuation, ownership and activity at a glance.
Market Cap
$327.7M
Cap Size
Small Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$558.0M
Inst. Activity
33 buys / 7 sells
Insider Activity
$0.00 buy / $2.0M sell
Insider Net $
-$2.0M
SEC Reports
5
Press Releases
3
Price chart 30d -30.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 other
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "
Jul 4, 2026 SEC
The federal district court granted BioAge Labs' motion to dismiss the securities class action lawsuit with prejudice and
COURT-RULING — Impact 7/10
Jun 30, 2026 Insider
Barton Shane acquired via exercise 4,290 shares
Principal Accounting Officer @ $10.85 ($46.5K)
Jun 30, 2026 Insider
Barton Shane sold 20,216 shares
Principal Accounting Officer @ $25.19 ($509.2K)
Jun 30, 2026 Insider
Barton Shane acquired via exercise 4,000 shares
Principal Accounting Officer @ $8.39 ($33.6K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
2,849,077 shares ($69.8M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
1,004,264 shares ($24.6M)
Jun 16, 2026 Press
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor)
Impact 3/10
Analyst ratings buy % +33.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 80% rate it Buy or better · 15 analysts
Strong Buy 6 40% Buy 6 40% Hold 3 20% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 9, 2026Roth CapitalREITERATEBuy 56%
Sep 8, 2026BTIGREITERATEBuy 53%
Aug 6, 2026BTIGREITERATEBuy 53%
Aug 3, 2026BTIGREITERATEBuy 53%
Jul 31, 2026NeedhamMAINTAINBuy 50%
May 27, 2026Roth CapitalINITIATEBuy 56%
May 13, 2026BTIGINITIATEBuy 53%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20266630080%
Aug 1, 20266630080%
Jul 1, 20266630080%
Jun 1, 20266630080%
May 1, 20265530077%
Apr 1, 20265530077%
Mar 1, 20265430075%
Feb 1, 20263440064%
Price targets
Where 8 covering analysts think BIOA trades over the next 12 months.
$35.63 +423.1% upside Strong Buy
Current$6.81 Low$20.00 Median$30.00 High$73.00 8 analysts
$20.00$73.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 5.2/10.Plus 3 press releases.
BULLISHCOURT-RULING7/10
The federal district court granted BioAge Labs' motion to dismiss the securities class action lawsui
Jul 4, 2026
BULLISH8-K7/10
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $
May 8, 2026
NEUTRALDEFA14A3/10
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify th
Apr 21, 2026
NEUTRAL1443/10
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares
Apr 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
other
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology comp
Sep 2, 2026
other
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology comp
Aug 31, 2026
short_interest_report
Short Interest: BIOA up 23% to 2.7M shares
Settlement 2026-08-31 | Days to cover: 4.72 | ≈5.93% of shares outstanding (est.)
Aug 12, 2026
earnings_calendar
BIOA Q2 2026 Earnings Scheduled — 2026-08-12
Aug 4, 2026
earnings_calendar
BIOA Q2 2026 Earnings Scheduled — 2026-08-04
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.61$-0.69–$-0.42-8.5%+0.0%2↑ 1↓$0.0B7
Next Q$-0.63$-0.76–$-0.4212.6%+0.0%2↑ 1↓$0.0B7
Current FY$-2.37$-2.77–$-1.94-6.0%+0.0%2↑ 2↓$0.0B7
Next FY$-2.41$-3.12–$-1.88-1.7%-2.3%3↑ 2↓$0.0B7
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.608—
7d ago$-0.608—
30d ago$-0.608—
60d ago$-0.656+0.049
90d ago$-0.656+0.049
Institutional ownership
Which big funds own BIOA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $558.0M total value (22,759,851 shares) as of 2026-Q2. Top holders: a16z, BlackRock,, Jupiter. Net buying activity: 33 institutions added/increased vs 7 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
a16z Capital Management, L.L.C.3,233,170$79.2M14.2%—
BlackRock, Inc.2,849,077$69.8M12.5%ADD +25.6%
Jupiter Topco LLC2,144,633$52.6M9.4%—
RA CAPITAL MANAGEMENT, L.P.1,671,648$41.0M7.3%NEW
VANGUARD CAPITAL MANAGEMENT LLC1,544,214$37.8M6.8%—
Polar Capital Holdings Plc1,072,344$26.3M4.7%NEW
STATE STREET CORP1,021,464$25.0M4.5%DOUBLED +101.2%
GEODE CAPITAL MANAGEMENT, LLC1,004,264$24.6M4.4%ADD +34.0%
D. E. Shaw & Co., Inc.742,761$18.2M3.3%—
BALYASNY ASSET MANAGEMENT L.P.702,858$17.2M3.1%TRIM -47.1%
Recent position changes
FundActionPrevCurrentChangeValue
BlackRock, Inc.ADD2,267,7562,849,077+25.6%$69.8M
GEODE CAPITAL MANAGEMENT, LLCADD749,2661,004,264+34.0%$24.6M
BALYASNY ASSET MANAGEMENT L.P.TRIM1,327,545702,858-47.1%$17.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD286,946410,165+42.9%$10.1M
DIMENSIONAL FUND ADVISORS LPADD214,546394,138+83.7%$9.7M
Walleye Capital LLCDOUBLED151,674354,395+133.7%$8.7M
Nuveen, LLCDOUBLED48,688349,142+617.1%$8.6M
NORTHERN TRUST CORPADD224,129343,166+53.1%$8.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM500,000300,000-40.0%$7.4M
GOLDMAN SACHS GROUP INCADD156,438270,769+73.1%$6.6M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 27 transactions. Net -$2.0M — $0.00 bought, $2.0M sold.
DateInsiderTitleTypeSharesPriceValue
Jun 30, 2026Barton ShanePrincipal Accounting OfficerEXERCISE4,290$10.85$46.5K
Jun 30, 2026Barton ShanePrincipal Accounting OfficerSELL20,216$25.19$509.2K
Jun 30, 2026Barton ShanePrincipal Accounting OfficerEXERCISE4,000$8.39$33.6K
Jun 30, 2026Barton ShanePrincipal Accounting OfficerEXERCISE4,065$4.30$17.5K
Jun 30, 2026Barton ShanePrincipal Accounting OfficerEXERCISE7,861$4.38$34.4K
Jun 29, 2026Barton ShanePrincipal Accounting OfficerEXERCISE9,301$10.85$100.9K
Jun 29, 2026Barton ShanePrincipal Accounting OfficerSELL42,350$25.21$1.1M
Jun 29, 2026Barton ShanePrincipal Accounting OfficerEXERCISE7,261$8.39$60.9K
Jun 29, 2026Barton ShanePrincipal Accounting OfficerEXERCISE8,958$4.30$38.5K
Jun 29, 2026Barton ShanePrincipal Accounting OfficerEXERCISE14,198$4.38$62.2K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BIOA.
Shares short
3,073,976
Settlement Sep 15, 2026
Change vs prior
+12.9%
Semi-monthly cycle
Days to cover
6.1
At avg daily volume
Of shares outstanding
≈6.7%
Estimate — not % of float
All BIOA filing & press-release reports (8)